🇺🇸 Sustanon 250 in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 14

Most-reported reactions

1. Drug Abuse — 2 reports (14.29%)
2. Hypersensitivity — 2 reports (14.29%)
3. Prostate Cancer — 2 reports (14.29%)
4. Ventricular Tachycardia — 2 reports (14.29%)
5. Adenocarcinoma — 1 report (7.14%)
6. Atrial Fibrillation — 1 report (7.14%)
7. Biliary Sepsis — 1 report (7.14%)
8. Blood Pressure Increased — 1 report (7.14%)
9. Breast Cancer — 1 report (7.14%)
10. Bronchitis — 1 report (7.14%)

Source database →

Frequently asked questions

Is Sustanon 250 approved in United States?

Sustanon 250 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sustanon 250 in United States?

Jules Bordet Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.